Pacific Edge Q4 25 volumes up, US adoption drives growth

Pacific Edge (NZX:PEB) announced improved Q4 25 results, with total laboratory throughput (TLT) rising to 7,577 tests from 7,092 in Q3 25. US TLT led the growth, climbing 11.7% to 6,490 tests, driven by an increase in unique ordering US clinicians to 914 from 866, and a rise in tests ordered per clinician to 7.1 from 6.7. The company credits continuing improvements in sales force efficiency, reaching 406 tests per sales FTE, and a seasonal rebound for the US growth. The recent American Urological Association (AUA) guideline inclusion of Cxbladder Triage with a 'Grade A' evidence rating is expected to further bolster sales. Asia Pacific TLT decreased 15% to 1,087 tests, reflecting a shift towards commercial testing and budgetary constraints. Total FY 25 volumes declined 11.5% to 28,894 tests, impacted by a reduction in sales force size due to previous Medicare coverage uncertainty.